Fukuda Denshi Co Ltd
TSE:6960
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5 860
8 590
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Fukuda Denshi Co Ltd
Fukuda Denshi Co Ltd
Cash & Cash Equivalents
Fukuda Denshi Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Cash & Cash Equivalents
¥64.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
|
Terumo Corp
TSE:4543
|
Cash & Cash Equivalents
¥194.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Olympus Corp
TSE:7733
|
Cash & Cash Equivalents
¥245.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
2%
|
|
|
Sysmex Corp
TSE:6869
|
Cash & Cash Equivalents
¥91.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Nihon Kohden Corp
TSE:6849
|
Cash & Cash Equivalents
¥34.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
9%
|
|
|
JEOL Ltd
TSE:6951
|
Cash & Cash Equivalents
¥39.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
36%
|
CAGR 10-Years
15%
|
|
Fukuda Denshi Co Ltd
Glance View
Fukuda Denshi Co Ltd. is a stalwart in the medical technology arena, having carved out a niche as a leading provider of innovative medical devices and systems. Founded in the mid-20th century, the company has stayed true to its mission of enhancing global healthcare with cutting-edge solutions. Over the years, Fukuda Denshi has evolved its product range to encompass a wide array of essential medical equipment, including electrocardiographs, patient monitoring systems, and ultrasonic diagnosis devices. These products are instrumental in hospitals and clinics for accurate patient diagnostics and monitoring, crucial for effective medical decision-making and improved patient outcomes. The company's journey from a modest operation to a global player is a testament to its commitment to research and development, enabling it to produce technologically advanced and reliable products. Fukuda Denshi's revenue model is primarily driven by the sales of its medical devices and systems across various healthcare settings globally. The company continually invests in innovation, ensuring that its products maintain a competitive edge in terms of functionality and reliability. By forming strategic alliances and partnerships, Fukuda Denshi expands its market reach and supports its distribution channels effectively. Additionally, the company provides comprehensive after-sales services, including maintenance and training, ensuring that healthcare providers can optimize the use of its devices. This service component not only enhances customer satisfaction but also establishes long-term relationships, contributing to recurring revenue streams and sustained business growth. Through a business model synergizing product excellence and strategic market engagement, Fukuda Denshi has solidified its position in the healthcare industry, meeting the growing demands for quality medical technology worldwide.
See Also
What is Fukuda Denshi Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
64.2B
JPY
Based on the financial report for Sep 30, 2024, Fukuda Denshi Co Ltd's Cash & Cash Equivalents amounts to 64.2B JPY.
What is Fukuda Denshi Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
11%
Over the last year, the Cash & Cash Equivalents growth was -9%. The average annual Cash & Cash Equivalents growth rates for Fukuda Denshi Co Ltd have been 5% over the past three years , 6% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet